FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D C	20540
vasiiiiiqton,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								<u>р.</u> [СНІ			ck all applica Director	ble)	ig Perso	10% O	wner
CORP.	3. Date of Earliest Transaction (Month/Day/Year) 11/23/2020							X Officer (give title below) Other (specify below) Chief Financial Officer							
				ate of	of Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Transaction Date				ion 2A. Deemed Execution Date,		3. 4. Securities Acquired (A) or			5. Amount of Securities Beneficially Owned Following			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct ndirect	7. Nature of Indirect Beneficial Ownership	
				Í	Code	v	Amount	(A) or (D)	Price	9	Transaction	n(s) d 4)			Instr. 4)
09/04/2	020				A		3,593,750	A	\$0.	007	3,593,	750			See Footnote ⁽²⁾
10/08/2	2020				D		718,750	D	\$0.0	00 ⁽⁷⁾	2,875,000				See Footnote ⁽²⁾
11/10/2	2020				D		575,000	D	\$0.0	00 ⁽⁷⁾	2,300,000				See Footnote ⁽²⁾
11/18/2	2020				S		30,000	D	\$0.0	2,270,000		000	I		See Footnote ⁽²⁾
11/18/2	020				S		30,000	D	\$0.0	0109	2,240,000				See Footnote ⁽²⁾
11/18/2	020			S		30,000	D	\$0.0	0109	2,210,000				See Footnote ⁽²⁾	
11/23/2	2020				A ⁽⁶⁾ 410,000		A	(1)	410,000				See Footnote ⁽²⁾	
											wned				
n Date, Ti	4. Transaction				6. Date Exerc		ate	of Securities Underlying Derivative Secur (Instr. 3 and 4)		Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		Form: Direct (D) or Indirec	Beneficial Ownership (Instr. 4)
С	ode	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	or Numb	ber		(Instr. 4)	str. 4)		
I	4 (6)		136,667		(3)	(4)	Class A Ordinary Shares	136,	,667	(1)	136,0	667	I	See Footnote ⁽²⁾
	2. Transact Date (Month/Day 10/08/2 10/08/2 11/18/2 11/18/2 11/18/2 11/23/2 - Derivat (e.g., p ned n Date, Day/Year) C C C C C C C C C	On-Derivative (Month/Day/Year) 09/04/2020 10/08/2020 11/18/2020 11/18/2020 11/18/2020 11/18/2020 - Derivative (e.g., puts, need n Date, Day/Year) 10/08/2020	Consort Cons	Consonance-I	Consonance-HFV	CORP. 3. Date of Earliest Transaction (1) 11/23/2020 4. If Amendment, Date of Origina 11/25/2020 2. Transaction Date (Month/Day/Year) 24. Deemed Execution Date, if any (Month/Day/Year) Code 09/04/2020 A 10/08/2020 D 11/10/2020 D 11/18/2020 S 11/18/2020 S 11/18/2020 S 11/18/2020 S 11/23/2020 S 11/23/2020 S 11/23/2020 S 11/23/2020 S 11/23/2020 S Code (e.g., puts, calls, warrants, option of Date, Code (instr. 8) S Number of Derivative Securities Acquired (A) or Disposed of (D) (instr. 3, 4 and 5) Date Exercises Code (in	CORP. 3. Date of Earliest Transaction (Month 11/23/2020 4. If Amendment, Date of Original File 11/25/2020 2A. Deemed Execution Date, (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) Code (Instr. 8) Code (Instr. 8)	3. Date of Earliest Transaction (Month/Day/Year) 11/23/2020 4. If Amendment, Date of Original Filed (Month/Day 11/25/2020 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction (Month/Day/Year) 3. Transaction Code (Instr. 8) 2. Transaction (Month/Day/Year) 2. Transaction (Month/Day/Year) 2. Transaction (Month/Day/Year) 3. Transaction Code (Instr. 8) 2. Transaction (Month/Day/Year) 2. Transaction (Month/Day/Year) 2. Transaction (Month/Day/Year) 3. Transaction (Month/Day/Year) 3. Transaction (Month/Day/Year) 4. Securities (Instr. 8) 3. Transaction (Month/Day/Year) 5. Transaction (Month/Day/Year) 5. Transaction (Month/Day/Year) 5. Number of (Month/Day/Year) 3. Transaction (Month/Day/Year) 5. Number of (Month/Day/Year) 6. Date Exercisable and Expiration Date (Month/Day/Year) 6. Date Exercisable and (Month/Day/Year) 6. Date Exercisable and (Month/Day/Year) 6. Date Exercisable (Month/Day/Year) 6.	Consonance-HFW Acquisition Corp. [CHI	CORP. 3. Date of Earliest Transaction (Month/Day/Year) 11/23/2020 4. If Amendment, Date of Original Filed (Month/Day/Year) 11/25/2020 2. Transaction Date (Month/Day/Year) 2. Poemed Date (Month/Day/Year) 2. Deemed Date (Instr. (Month/Day/Year) 2. Defivative Securities (Month/Day/Year) 2. Defivative Sec	Consonance-HFW Acquisition Corp. [CHFW Check]	Consonance-HFW Acquisition Corp. CHFW Check all application Corp. CORP. CORP. Corp. Corp. Check all application Corp. Check all application Check Ch	Consonance	Consonance-HFW Acquisition Corp. CHFW Check all applicable Director X Director Director X Director X Director X Director Direc	Consonance-HFW Acquisition Corp. CHFW Check all applicable) Director 10% 0 Other (pive title Director 10% 0 Other (pi

- 1. Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for \$10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at \$11.50 per share.
- 2. The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
- 3. The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering,
- 4. The warrants will expire five years after the completion of the Issuer's initial business combination.
- 5. Includes 136,667 warrants underlying the units referred to in footnote 1.
- 6. This Form 4 amendment is being filed to correct the original Form 4 filed on November 25, 2020. The original Form 4 had the incorrect transaction code, and did not include reporting of all of the required
- 7. The Sponsor contributed these shares back to the Issuer for no consideration.

Remarks:

/s/ Kevin Livingston

05/19/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.